Status:
COMPLETED
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
Lead Sponsor:
Watson Pharmaceuticals
Conditions:
Benign Prostatic Hyperplasia
Eligibility:
MALE
50+ years
Phase:
PHASE3
Brief Summary
A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
Detailed Description
This will be a multi-center, double-blind, placebo controlled, parallel, 12 week treatment trial in men with signs and symptoms of benign prostatic hyperplasia. the following procedures are utilized: ...
Eligibility Criteria
Inclusion
- Males in good general health and at least 50 years of age, with symptoms of moderate to severe BPH.
Exclusion
- Medical conditions that would confound the efficacy evaluation.
- Medical conditions in which it would be unsafe to use an alpha-blocker.
- The use of concomitant drugs that would confound the efficacy evaluation.
- The use of concomitant drugs that would be unsafe with this alpha-blocker.
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
462 Patients enrolled
Trial Details
Trial ID
NCT00224120
Start Date
May 1 2005
End Date
May 1 2006
Last Update
December 15 2009
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
Carmichael, California, United States
3
Fresno, California, United States
4
Laguna Woods, California, United States